Pod-Type Etonogestrel + Ethinyl Estradiol + QGriffithsin Intravaginal Ring
EEQ IVR
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Oak Crest Institute of Science, Population Council
Details
- API: Etonogestrel, Ethinyl Estradiol, Lectin Qgriffithsin
- Target: Estrogen Receptor, Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Ovulation Inhibition
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and HIV prevention. It could reduce both the emergence of drug-resistant HIV and the concern of potential increased risk of HIV transmission as well as common irregular bleeding complaints.
Product Status
Active Pre-Clinical Research
History
2021: An NIH grant was awarded to develop a multipurpose prevention technology intravaginal ring that releases a safe and effective combination of an estrogen, a progestin, and a non-ARV antiviral agent to prevent pregnancy and HIV infection.
2022: A three-month pilot crossover clinical study began with 24 US couples. The study compares adherence, preference, and acceptability of three non-medicated silicone intravaginal rings.